Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elo-KRd in Newly Diagnosed Multiple Myeloma
NCT02969837Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Jul 2017
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by University of Chicago. Primary endpoints: Stringent Complete Response at 24 months, Minimal Residual Disease Negativity at 8 months and 1 more. Started Jul 2017; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02969837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969837.